An ongoing dialogue on HIV/AIDS, infectious diseases,
January 20th, 2011
A New Antiretroviral Drug Class, and a Movie
In my email in-box today was a very odd press release, referring to this paper, just published in PLoS ONE. With the subject line, “Koronis – Clinical Trial Results Demonstrate Promise for First Non-suppressive HIV Drug,” it included the following information:
Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism. Koronis is planning a follow-on Phase 2 trial to determine the treatment duration required to achieve a clinically meaningful decrease in a patient’s viral load.
First, you don’t want to be known as a “Non-suppressive HIV drug.” And second, while I get the premise that giving a drug that leads to mutations probably indicates some sort of selection pressure, it’s a long way from this observation to an actual antiviral agent.
But who knows? This may be the next great antiviral drug class, and the phrase “Viral Decay Acceleration” — with its faint echo of 1950s sci-fi movies — sounds incredibly cool. According to the company’s web site, VDA “exploits the strength of a virus – its high mutation rate – to target its collapse.”
So dim the lights, grab some popcorn, and watch the movie here.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Case 21-2026: A 28-Year-Old Man with Headache and Vision Loss in the Right Eye July 23, 2026A 28-year-old man was admitted to the hospital because of monocular vision loss. Examination showed optic disk edema, and imaging revealed liver lesions and lymphadenopathy. A diagnosis was made.
- Klebsiella Brain Abscess and Evolution of Heterovirulence in the Urinary Tract July 23, 2026In a patient with a staghorn calculus, chronic urinary tract infection with Klebsiella pneumoniae enabled within-patient evolution of virulence properties that facilitated dissemination of infection, leading to a brain abscess.
- The Best of Both Worlds — Using Clinical Trial and Observational Data to Evaluate Vaccine Protection July 23, 2026Well-designed observational studies are critical to advancing understanding of the effects of vaccines. But they are often dismissed as lacking the methodologic rigor necessary to inform policymaking.
- Neurocysticercosis July 23, 2026A 52-year-old woman presented with a 4-month history of headache and visual hallucinations. MRI of the brain showed cystic lesions containing bright nodules.
- National Elimination of Hepatitis C — The Case for Starting in Prisons and Jails July 23, 2026The United States could take meaningful steps toward eliminating hepatitis C by broadly testing and treating people who are involved in the criminal legal system.
- Case 21-2026: A 28-Year-Old Man with Headache and Vision Loss in the Right Eye July 23, 2026